Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Genoa – page 49

715 clinical trials in Genoa, Italy across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Genoa at a glance
715
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

715 trials in Genoa

Open in trial search

Diffuse large B-cell lymphoma

Not recruiting

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Incyte Corp.

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Fibrodysplasia ossificans progressiva

Not recruiting

Study on the Effects of Fidrisertib for Treating Fibrodysplasia Ossificans Progressiva in Children and Adults

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:(R)‑Tetrahydrofuran‑3‑Yl 4‑(6‑(5‑(4‑Ethoxy‑1‑Isopropylpiperidin‑4‑Yl)Pyridin-2-Yl)Pyrrolo[1,2-B]Pyridazin-4-Yl)Piperazine-1-Carboxylate Sesquisuccinate
  • Sponsor:Clementia Pharmaceuticals Inc. An Ipsen Company

Asthmatic crisis

Not recruiting

Study on the Effects of Verekitug (UPB-101) for Adults with Severe Asthma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Cystic fibrosis

Not recruiting

Study on the Effects of Dirocaftor, Posenacaftor, and Nesolicaftor for Adults with Cystic Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dirocaftor
  • Sponsor:Universitair Medisch Centrum Utrecht

Metastatic malignant melanoma

Not recruiting

Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:IO102 hydrochloride
  • Sponsor:Io Biotech ApS

Paediatric acute-onset neuropsychiatric syndrome

Not recruiting

Study Comparing Human Normal Immunoglobulin and Placebo for Children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
  • Sponsor:Takeda Development Center Americas Inc.

Acute myeloid leukaemia

Not recruiting

Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:Novartis Pharma AG

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effectiveness and Safety of Nipocalimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Pneumonia

Not recruiting

Study on the Effects of Amikacin Liposome Inhalation, Azithromycin, and Ethambutol in Adults with Newly Diagnosed Nontuberculous Mycobacterial Lung Infection

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin
  • Sponsor:Insmed Inc.

Fibrodysplasia ossificans progressiva

Not recruiting

Study on the Safety and Effectiveness of Garetosmab for Adults with Fibrodysplasia Ossificans Progressiva

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Garetosmab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Genoa

What the registry says about research in the country

01 Infectious Disease Research

Clinical studies focusing on viral infections and prevention strategies, including trials evaluating vaccines against Herpes Zoster and Cytomegalovirus in healthy adults.

  • Vaccine effectiveness studies
  • Immune response monitoring
  • Prevention protocols

Research includes evaluation of antibiotic protocols in dental procedures and viral-specific treatments for immunocompromised patients.

02 Oncology Studies

Innovative research in cancer treatment, including trials for breast cancer prevention, advanced solid tumors, and targeted therapies for colorectal cancer.

  • Preventive interventions
  • Novel combination therapies
  • Diagnostic imaging

Studies encompass both early intervention strategies and treatments for advanced stages of various cancers.

03 Neurological Disorders

Investigations into treatments for Multiple Sclerosis and other neurological conditions, with focus on disease progression and innovative therapies.

  • Progressive MS treatments
  • Neuromuscular monitoring
  • Safety assessments

Clinical trials evaluating new therapeutic approaches for various neurological conditions including Dravet Syndrome.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.